SR58611A
Sponsors
Sanofi
Conditions
Anxiety DisorderAnxiety DisordersDepressive DisorderMajor DepressionMajor Depressive Disorder
Phase 3
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
CompletedNCT00252343
Start: 2005-09-30End: 2007-02-28Updated: 2009-03-12
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
CompletedNCT00252330
Start: 2005-09-30End: 2007-01-31Updated: 2009-03-12
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
CompletedNCT00252356
Start: 2005-09-30End: 2007-05-31Updated: 2009-03-12
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
CompletedNCT00266747
Start: 2005-12-31End: 2007-01-31Updated: 2009-03-12
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
CompletedNCT00319709
Start: 2006-04-30End: 2007-08-31Updated: 2009-03-12
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
CompletedNCT00332891
Start: 2006-03-31End: 2007-04-30Updated: 2009-03-09
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
CompletedNCT00345098
Start: 2006-05-31End: 2008-02-29Updated: 2009-03-12
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
TerminatedNCT00397098
Start: 2006-11-30End: 2007-09-30Updated: 2009-03-12
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
CompletedNCT00432614
Start: 2007-01-31End: 2008-02-29Updated: 2009-03-25
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder
TerminatedNCT00535340
Start: 2007-03-31End: 2007-08-31Updated: 2009-03-12